Argos Therapeutics, Inc.
(Other OTC/NBB : ARGS)

( )
ARGS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 5.24%77.980.0%$2554.93m
NVAXNovavax, Inc. 8.92%155.87102.0%$1168.61m
GILDGilead Sciences, Inc. 3.16%71.731.0%$539.45m
AMGNAmgen, Inc. 1.10%247.361.3%$526.20m
REGNRegeneron Pharmaceuticals, Inc. 2.07%645.182.5%$472.99m
BNTXBioNTech SE 4.09%85.470.0%$434.80m
VRTXVertex Pharmaceuticals, Inc. 2.77%279.521.9%$391.51m
BIIBBiogen, Inc. 1.26%278.161.6%$330.55m
ILMNIllumina, Inc. 4.11%397.863.5%$328.09m
VXRTVaxart, Inc. -1.49%9.250.0%$322.37m
SRNESorrento Therapeutics, Inc. 9.53%9.771.8%$256.18m
IBIOiBio, Inc. 2.25%4.540.2%$195.81m
SGENSeattle Genetics, Inc. 1.67%169.046.1%$182.21m
ALXNAlexion Pharmaceuticals, Inc. 2.30%104.852.0%$174.99m
EBSEmergent BioSolutions, Inc. 6.08%118.006.4%$155.51m

Company Profile

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.